"The Company intends to raise additional capital during and following the first quarter of 2018 to fund operations and strengthen its financial position. The Company also intends to pursue additional licensing opportunities, some of which are expected to contain up front payments."

Good. They need some $

"The Company has received a 60-day extension to April 12, 2018 for the TSX’s review of the Company’s compliance with all of the TSX listing requirements."

Good. Hopefully the additional capital raised will help with TSX review.

"For 2018, the Company targets commencing enrollment of US-based patients in its Phase 3 BETonMACE trial in the first half of 2018..."

Uh-oh. What happened to Q1 for this goal stated in December 2017 and January 2018

"Furthermore, the Company targets randomizing its first patient in its Phase 2a Kidney Dialysis clinical trial and enrolling its first patient in its Fabry Disease clinical trial during the second quarter of 2018."

Hopefully this statement holds. Kidney trial was first posted on ClinicalTrials.gov last May and they have revised the start date a few times already (currently March 15, 2018). Q2 2018 start for kidney trial would be another delay, but hopefully this is the last delay. Fabry trial as been listed as April 30, 2018 start since last October but was also originally posted on ClinicalTrials.gov with an earlier start date before the revised delay. Hopefully Q2 2018 for Fabry holds too. All depends on raising funds/signing deals I guess.

BearDownAZ